JenaValve Highlights Early U.S. Commercial Use of Trilogy TAVR System

According to a recent LinkedIn post from JenaValve Technology Inc, the company is highlighting the first commercial U.S. cases of its Trilogy transcatheter aortic valve replacement (TAVR) system for aortic regurgitation, performed at Columbia University Irving Medical Center. The post credits Columbia’s heart team for involvement from clinical research through to the launch of this FDA‑approved therapy for high‑risk aortic regurgitation patients.

The post suggests that Trilogy is transitioning from clinical development into early commercial use in the U.S., which may mark a key inflection point for JenaValve’s revenue potential if adoption scales. Successful early procedures at a leading academic center could support broader clinical acceptance, although the pace of commercialization will depend on reimbursement, physician training, comparative outcomes, and competition in the structural heart market.

By emphasizing collaboration with a high‑profile institution, the content may signal JenaValve’s strategy to build clinical credibility and real‑world evidence to support further uptake. For investors, sustained procedure volume growth, additional site activations beyond the initial three centers, and expanded indications or geographies would be important milestones to assess the long‑term commercial and valuation impact of the Trilogy platform.

The inclusion of safety cautions and links to indications and contraindications aligns with typical medical device promotion practices in the U.S. and underscores that use is restricted to physicians. While the post is promotional in nature, it indirectly points to regulatory progress and early commercial traction in a specialized, high‑risk patient segment, which could influence JenaValve’s competitive position within the TAVR landscape over time.